On December 8, 2025, Structure Therapeutics Inc. reported strong results from its ACCESS clinical program for aleniglipron, showing a placebo-adjusted mean weight loss of 11.3% at 120 mg and 15.3% at 240 mg over 36 weeks. This data supports advancing to Phase 3 trials planned for mid-2026.